Autosomal-dominant polycystic kidney disease: perspectives of treatment


Cite item

Full Text

Abstract

Perspectives of treatment of autosomal-dominant polycystic kidney disease, especially target therapeutic strategies, are discussed

About the authors

- -

References

  1. Torres V.E., Harris P.C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009; 76: 149-168
  2. Perrone R.D., Ruthazer R., Terrin N.C. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001; 38: 777-784
  3. Parfrey P.S., Barrett B.J. Hypertension in autosomal dominant polycystic kidney disease. Curr. Opin. Nephrol. Hypertens 1995; 4: 460-464
  4. Schrier R.W., Johnson A.M., McFann K., Chapman A.B. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64:1792-1799
  5. Idrizi A., Barbullushi M., Strakosha A. et al. The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease. G. Ital. Nefrol. 2007; 24: 595-599
  6. Covic A., Mititiuc I., Gusbeth-Tatomir P., Goldsmith D.J. The reproducibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairment - a prospective ABPM study. J. Nephrol 2002;15: 497-506
  7. Chapman A.B., Johnson A.M., Rainguet S. et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1997; 8: 1292-1297
  8. Torres V.E., King B.F., Chapman A.B. et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2: 112-120
  9. Chapman A.B., Johnson A., Gabow P.A., Schrier R.W. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096
  10. Wang D., Iversen J., Wilcox C.S., Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388
  11. Chapman A.B., Stepniakowski K, Ranbari-Oskoui F. Hypertension in autosomal polycystic kidney disease. Adv. Chronic Kidney Dis. 2010 ; 17(2) : 153-163
  12. Kanno Y., Okada H., Moriwaki K. et al. The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats. Hypertens Res. 2002; 25(6): 939-943
  13. Zeltner R., Poliak R., Stiasny B. et al. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2008; 23(2): 573-579
  14. Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334(15): 939-945
  15. Ulusoy S., Ozkan G., Orem C. et al. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Ren. Fail. 2010; 32(8): 913-917
  16. Amico P., Kalbermatter S., Kiss D. et al. Aliskiren corrects recurrent hyperreninemia and hyperaldosteronism in autosomal dominant polycystic kidney disease. Clin. Nephrol. 2009; 72(3): 237-239
  17. Chapman A.B. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD Studies. Clin J Am Soc Nephrol 2008; 3: 1197-1204
  18. Bae K.T., Commean P.K., Lee J. Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assisted Tomogr 2000; 24: 614-619
  19. Grantham J.J., Torres V.E., Chapman A.B. et al. Volume progressionin polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130
  20. Chapman A.B., Guay-Woodford L., Grantham J.J. et al. Renal structure in early autosomal dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney Int 2003; 64: 1035-1045
  21. Yamaguchi T., Pelling J.C., Ramaswamy N.T. et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000; 57: 1460-1471
  22. Masyuk A.I., Masyuk T.V., Splinter P.L, et al. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131: 911-920
  23. van Keimpema L., Nevens F., Vanslembrouck R. et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009; 137(5): 1661-8.e1-2
  24. Hogan M.C., Masyuk T.V., Page L.J. et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J. Am. Soc. Nephrol. 2010; 21(6): 1052-1061
  25. Meijer E., Boertien W.E., Zietse R., Gansevoort R.T. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2011; 34(4): 235-244
  26. Nagao S., Nishii K., Katsuyama M. et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17(8): 2220-2227
  27. Chapman A.B., Torres V.E., Grantham J.J. et al. A phase IIB pilot study fof the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA) in patients with ADPKD. J. Am. Soc. Nephrol 2005; 16: 68A
  28. Zafar I., Tao Y., Falk S. et al. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 2007; 293: F854-F859
  29. van Dijk M.A., Kamper A.M., van Veen S. et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16: 2152-2157
  30. Leuenroth S.J., Okuhara D., Shotwell J.D. et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007;104: 4389-4394
  31. Rankin C.A., Itoh Y., Tian C. et al. Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease. J. Am. Soc. Nephrol. 1999; 10(2): 210-217
  32. Obermuller N., Morente N., Kranzlin B. et al. A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol 2001; 280(3): F540-F550
  33. Sweeney W.E. Jr., Hamahira K., Sweeney J. et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003; 64: 1310-1319
  34. Serra A.L., Poster D., Kistler A.D. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363(9): 820-829

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies